# ACR REVIEW 2026

#ACReview26

Lo mejor de ACR



Sociedad Española de Reumatología

PATROCINADO POR: AstraZeneca · Gebro Pharma · Lilly A MEDICINE COMPANY

ACR REVIEW 2026

# Lo mejor de LES, Sjögren y Esclerosis Sistémica

**Cristiana Sieiro Santos**

Centre for Musculoskeletal Research, School of Biological Sciences,
Faculty of Biology, Medicine and Health,
University of Manchester, Manchester, UK


Manchester University NHS Foundation Trust (MFT)

Sociedad Española de Reumatología

PATROCINADO POR: AstraZeneca Gebro Pharma Lilly A MEDICINE COMPANY


ABSTRACT NUMBER: 1960

# Amplification of the Th17/IL-17 Pathway Activation Marks the Transition from Very Early Systemic Sclerosis (VEDOSS) to Established Systemic Sclerosis: A Multi-Omics Analysis




ABSTRACT NUMBER: 1969

# Proteomic Profiling Reveals Immune, Metabolic and Tissue Stress Pathways Associated with Articular Disease Burden in Systemic Sclerosis




ABSTRACT NUMBER: 1974

# Systemic sclerosis patients with different Scleroderma Clinical Trial Consortium Activity Index (SCTC-AI) levels display distinct transcriptomic and cellular signatures




ABSTRACT NUMBER: 2839

# A New Endpoint for SLE Clinical Trials: The Treatment Response Measure for Systemic Lupus Erythematosus Clinical Trials (TRM-SLE)



ABSTRACT NUMBER: 2379


# Ultrasound Focal Lesions and Persistent Parotid Swelling as Predictors of Salivary Gland Lymphoma in Sjögren's Disease




- **Lesiones focales ecográficas y tumefacción parotídea persistente están asociadas a linfoma MALT en Sjögren**
- La puntuación ecográfica global (OMERACT) **no permite diferenciación clínica**
- **Evaluación ecográfica dirigida + integración clínica y serológica apoya la selección de pacientes para biopsia**

ABSTRACT NUMBER: 2364


# Ianalumab reduces disease activity across ESSDAI domains: Post hoc analysis from the pooled Phase-3 NEPTUNUS-1 and NEPTUNUS-2 trials in Sjögren's disease




*Análisis post hoc; los porcentajes por dominio reflejan subgrupos pequeños. No se muestran estadísticas por dominio ni datos de seguridad/síntomas.*


ABSTRACT NUMBER: 2910

# The CD20xCD3 T-Cell Engager PRO-203 Induces Deep B-Cell Depletion and Clinical Improvement in Patients with Systemic Autoimmune Rheumatic Diseases - A Case-Series in Treatment-Refractory Patients



ABSTRACT NUMBER: 2256

# Increased Arterial Stiffness in Younger and Low-Risk Individuals with Systemic Lupus Erythematosus Predicts Atherosclerotic Plaque Progression: A Matched Comparative Study with Rheumatoid Arthritis, Diabetes Mellitus, and Healthy Controls



# ACR REVIEW 2026

#ACReview26

Lo mejor de ACR



Sociedad Española de Reumatología

PATROCINADO POR: AstraZeneca · Gebro Pharma · Lilly A MEDICINE COMPANY